BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD
NCT00846768
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
47
Enrollment
INDUSTRY
Sponsor class
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG:
BI 1744 CL
Sponsor
Boehringer Ingelheim